Lannett Receives FDA Approval for Dronabinol Capsules

Lannett Company, Inc. (LCI) announced on May 21 that they have received FDA approval for Dronabinol Capsules. The drug is the therapeutic equivalent to Marinol Capsules, and only a handful of suppliers manufacture generic versions of the drug for the US market. Dronabinol Capsules can be used to treat patients with loss of appetite due to nausea and is often prescribed to cancer patients undergoing chemotherapy.

 

Sonal detected the event at 6:53 am. The next trade took place at 7:00 am for $16.50. Regular market trading opened at $16.25. The stock price moved higher throughout the event day and closed at $17.05.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!